Surgical robotics company Virtual Incision Corp., of Lincoln, Neb., has raised $20 million in a series B+ financing led by returning investor Bluestem Capital. The funds are earmarked for clinical and regulatory programs aimed at commercializing the company’s MIRA (miniaturized in vivo robotic assistant) surgical robotic platform.
Adagene Inc., an immuno-oncology company with operations in both the U.S. and China, has raised a $69 million series D financing to support its development of two monoclonal antibodies (MAbs) and extension of its technology-driven in-house antibody design platform. Its two lead candidates are a phase I MAb targeting CD137 and a preclinical MAb targeting CTLA4.
With a newly raised $60 million series B financing, Tarsus Pharmaceuticals Inc. plans to start a phase IIb/III trial of its lead product, TP-03, for treating demodex blepharitis, and to jumpstart two other clinical programs.
The obesity problem is one that is affecting a growing number of people globally. With both device and drug companies looking to take on the challenge of combating the problem, Allurion Technologies Inc. has set its sights on advancing a new approach in the U.S. Now, the Natick, Mass.-based company has scored $34 million in new funding through a securities financing and a growth capital term loan. The round was led by Novalis Lifesciences and Romulus Capital, with participation from Ido Investments and ex-Covidien CEO Jose Almeida.
LONDON – Northsea Therapeutics BV has closed a $40 million series B, providing the means to complete the ongoing U.S. phase IIb trial of its lead product for treating nonalcoholic steatohepatitis (NASH) and to launch clinical trials of two more products.
Novome Biotechnologies Inc., a startup developing a hyperoxaluria therapy based on controlled colonization of the gut with engineered bacteria, has landed a $33 million series A financing and appointed former Achaogen Inc. chief Blake Wise as CEO.
An aspect of artificial intelligence (AI) that’s often misunderstood is its power, something Deep Genomics Inc.’s founder and CEO, Brendan Frey, does his best to clarify for collaborators and his employees. “One problem of AI is thinking of it as a magic black box that can solve any issue,” Frey told BioWorld soon after the company announced a $40 million series B financing. “If you take that approach, it won’t help.”